Long-Acting C-Terminal Peptide–Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children | Zendy

Nataliya Zelinska | Zendy; Violeta Iotova | Zendy; Julia Skorodok | Zendy; Oleg Malievsky | Zendy; Valentina Peterkova | Zendy; Lubov N. Samsonova | Zendy; Ron G. Rosenfeld | Zendy; Zvi Zadik | Zendy; Michal JaronMendelson | Zendy; Ronit Koren | Zendy; Leanne Amitzi | Zendy; Dmitri Raduk | Zendy; Oren Hershkovitz | Zendy; Gili Hart | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-Acting C-Terminal Peptide–Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children

Author(s) -

Nataliya Zelinska,

Violeta Iotova,

Julia Skorodok,

Oleg Malievsky,

Valentina Peterkova,

Lubov N. Samsonova,

Ron G. Rosenfeld,

Zvi Zadik,

Michal JaronMendelson,

Ronit Koren,

Leanne Amitzi,

Dmitri Raduk,

Oren Hershkovitz,

Gili Hart

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-3547

Subject(s) - tolerability , mod , medicine , adverse effect , dosing , regimen , pharmacology , endocrinology , artificial intelligence , computer science

Daily injections are required for growth hormone (GH) replacement therapy, which may cause low compliance as a result of inconvenience and distress in patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research